Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.58 |
| ▸ | F3 | P13726 | 1/20 | 0.58 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.58 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.58 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.58 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.58 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.58 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.58 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niacin SCHEMBL810524 | 0.91 | ALDH1A1 (0.57) | F7F3SARM1SIRT2SIRT6 | |
| Adonitol SCHEMBL27591282 | 0.83 | F7 (0.69) | F7F3SARM1SIRT2SIRT6 | |
| Mannitol SCHEMBL9807801 | 0.83 | F7 (0.69) | F7F3SARM1SIRT2SIRT6 | |
| Mannitol SCHEMBL21807508 | 0.81 | F7 (0.61) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL4472261 | 0.80 | SIRT2 (0.59) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL28309509 | 0.80 | SIRT2 (0.59) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL27877775 | 0.80 | F7 (0.73) | F7F3SARM1SIRT2SIRT6 | |
| Cadaverine Tartrate SCHEMBL28825318 | 0.79 | F7 (0.51) | F7F3SARM1SIRT2SIRT6 | |
| Xylose SCHEMBL23925306 | 0.79 | F7 (0.58) | F7F3SARM1SIRT2SIRT6 | |
| Xylose SCHEMBL938610 | 0.79 | F7 (0.58) | F7F3SARM1SIRT2SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040156873-A1 | Topically Bioavailable Acne and Rosacea Treatment Compositions | GUPTA SHYAM K (US) | 2004-08-12 | — | — | US | claimed |
| US-20040081672-A1 | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging | GUPTA SHYAM K (US) | 2004-04-29 | — | — | US | claimed |
| US-10173943-B2 | Non-corrosive nitrification inhibitor polar solvent formulation | DOW AGROSCIENCES, LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-10173942-B2 | Non-corrosive nitrification inhibitor polar solvent formulation | DOW AGROSCIENCES, LLC (US) | 2019-01-08 | — | — | US | disclosed |
| WO-2017069827-A1 | NON-CORROSIVE NITRIFICATION INHIBITOR POLAR SOLVENT FORMULATION | DOW AGROSCIENCES, LLC (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017069828-A1 | NON-CORROSIVE NITRIFICATION INHIBITOR POLAR SOLVENT FORMULATION | DOW AGROSCIENCES, LLC (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20160332930-A1 | NON-CORROSIVE NITRIFICATION INHIBITOR POLAR SOLVENT FORMULATION | SPECIALTY OPERATIONS FRANCE (FR) | 2016-11-17 | — | — | US | disclosed |
| US-20160332931-A1 | NON-CORROSIVE NITRIFICATION INHIBITOR POLAR SOLVENT FORMULATION | SPECIALTY OPERATIONS FRANCE (FR) | 2016-11-17 | — | — | US | disclosed |
| US-20160220536-A1 | USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION | UNIV OHIO (US) | 2016-08-04 | — | — | US | disclosed |
| US-9326972-B2 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | OHIO UNIVERSITY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20120238610-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | OHIO UNIVERSITY | 2012-09-20 | — | — | US | disclosed |
| US-20100004304-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND PANCREATIC CANCER | OHIO UNIVERSITY | 2010-01-07 | — | — | US | disclosed |
| EP-1896015-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTORS | The Interthyr Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006124676-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTORS | THE INTERTHYR CORPORATION (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060211752-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | BENAVIDES-PERALTA, URUGUAYSITO LORELEY (UY) | 2006-09-21 | — | — | US | disclosed |
| US-20060147508-A1 | Concurrent Enhancement of Skin Penetration of Organic Base Active Agents and Organic Hydroxy Acid Active Agents as Their Ion-Pair Complexes | BIODERM RESEARCH (US) | 2006-07-06 | — | — | US | disclosed |
| WO-2006023710-A2 | COSMETIC OR PHARMACEUTICAL COMPOSITION FOR SKIN CARE | INFINITY2 HEALTH SCIENCES, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060039887-A1 | Cosmetic or pharmaceutical composition for skin care | INFINITY2 HEALTH SCIENCES, INC. | 2006-02-23 | — | — | US | disclosed |
| US-20040228884-A1 | Ion-pair delivery system for cosmetic and pharmaceutical compositions | GUPTA SHYAM K (US) | 2004-11-18 | — | — | US | disclosed |
| US-20040081672-A1 | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging | GUPTA SHYAM K (US) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211752-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | TLR3, IRF3, TLR4 | F7 3574/4885F3 337/4885SARM1 3854/4885 |
| US-20120238610-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | IRF3, TLR3, TLR4 | F7 3797/4885F3 671/4885SARM1 3530/4885 |
| US-20160220536-A1 | USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION | IRF3, TLR3, TLR4 | F7 3797/4885F3 671/4885SARM1 3530/4885 |
| US-20100004304-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND PANCREATIC CANCER | STAT3, STAT6, TLR3 | F7 1753/4885F3 587/4885SARM1 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.